Endocytosis and Trafficking of Heparan Sulfate Proteoglycans in Triple-Negative Breast Cancer Cells Unraveled with a Polycationic Peptide.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
    • Publication Information:
      Original Publication: Basel, Switzerland : MDPI, [2000-
    • Subject Terms:
      Adenocarcinoma/*metabolism ; Endocytosis/*physiology ; Heparan Sulfate Proteoglycans/*metabolism ; Molecular Imaging/*methods ; Peptides/*chemistry ; Triple Negative Breast Neoplasms/*metabolism; Adenocarcinoma/pathology ; Cations ; Cell Movement ; Female ; Humans ; Microscopy, Fluorescence ; Peptides/pharmacokinetics ; Protein Transport ; Triple Negative Breast Neoplasms/pathology ; Tumor Cells, Cultured
    • Abstract:
      The process of heparan sulfate proteoglycan (HSPG) internalization has been described as following different pathways. The tumor-specific branched NT4 peptide has been demonstrated to bind HSPGs on the plasma membrane and to be internalized in tumor cell lines. The polycationic peptide has been also shown to impair migration of different cancer cell lines in 2D and 3D models. Our hypothesis was that HSPG endocytosis could affect two important phenomena of cancer development: cell migration and nourishment. Using NT4 as an experimental tool mimicking heparin-binding ligands, we studied endocytosis and trafficking of HSPGs in a triple-negative human breast cancer cell line, MDA-MB-231. The peptide entered cells employing caveolin- or clathrin-dependent endocytosis and macropinocytosis, in line with what is already known about HSPGs. NT4 then localized in early and late endosomes in a time-dependent manner. The peptide had a negative effect on CDC42-activation triggered by EGF. The effect can be explained if we consider NT4 a competitive inhibitor of EGF on HS that impairs the co-receptor activity of the proteoglycan, reducing EGFR activation. Reduction of the invasive migratory phenotype of MDA-MB-231 induced by NT4 can be ascribed to this effect. RhoA activation was damped by EGF in MDA-MB-231. Indeed, EGF reduced RhoA-GTP and NT4 did not interfere with this receptor-mediated signaling. On the other hand, the peptide alone determined a small but solid reduction in active RhoA in breast cancer cells. This result supports the observation of few other studies, showing direct activation of the GTPase through HSPG, not mediated by EGF/EGFR.
    • References:
      Cell Signal. 2011 Sep;23(9):1415-23. (PMID: 21515363)
      Cell Commun Signal. 2015 Apr 10;13:24. (PMID: 25889964)
      Traffic. 2007 Apr;8(4):389-401. (PMID: 17394486)
      PLoS One. 2018 Mar 22;13(3):e0194744. (PMID: 29566097)
      Nat Commun. 2020 Aug 26;11(1):4261. (PMID: 32848136)
      J Med Chem. 2013 Jun 27;56(12):5009-18. (PMID: 23713525)
      Nature. 2019 Apr;568(7752):410-414. (PMID: 30918400)
      Cold Spring Harb Perspect Biol. 2011 Jul 01;3(7):. (PMID: 21690215)
      Virology. 2018 Feb;515:92-107. (PMID: 29277006)
      Proc Natl Acad Sci U S A. 2020 Nov 3;117(44):27400-27411. (PMID: 33087579)
      Nat Rev Mol Cell Biol. 2007 Aug;8(8):603-12. (PMID: 17609668)
      Adv Biol Regul. 2017 Jan;63:132-139. (PMID: 27658318)
      Sci Rep. 2017 Oct 30;7(1):14373. (PMID: 29085061)
      Arterioscler Thromb Vasc Biol. 2018 Jan;38(1):102-113. (PMID: 29162604)
      FEBS J. 2020 Jun 15;:. (PMID: 32542850)
      Mol Cancer Ther. 2007 Sep;6(9):2441-8. (PMID: 17766836)
      J Cell Sci. 2004 Mar 15;117(Pt 8):1291-300. (PMID: 15020669)
      Mol Cells. 2013 Dec;36(6):548-55. (PMID: 24241683)
      Biochim Biophys Acta. 2015 Apr;1855(2):276-300. (PMID: 25829250)
      J Biol Chem. 2005 May 27;280(21):20516-23. (PMID: 15778504)
      Virology. 2016 Jan;487:172-87. (PMID: 26539799)
      Curr Opin Cell Biol. 2019 Aug;59:34-39. (PMID: 30981180)
      Front Cell Dev Biol. 2019 Jul 16;7:127. (PMID: 31380367)
      Methods Mol Biol. 2008;440:15-33. (PMID: 18369934)
      Sci Rep. 2016 Jun 03;6:27174. (PMID: 27255651)
      Cell Rep. 2019 Jan 2;26(1):79-93.e8. (PMID: 30605688)
      Sci Rep. 2017 Dec 4;7(1):16873. (PMID: 29203889)
      FASEB J. 2020 Jun 12;:. (PMID: 32530114)
      J Biol Chem. 2003 Nov 21;278(47):46590-5. (PMID: 12972419)
      Mol Cell Biol. 2014 Jul;34(14):2635-49. (PMID: 24820414)
      Curr Cancer Drug Targets. 2010 Nov;10(7):695-704. (PMID: 20578987)
      Sci Rep. 2015 Dec 02;5:17736. (PMID: 26626158)
      Biochem Res Int. 2020 Feb 11;2020:4186308. (PMID: 32104603)
      Matrix Biol. 2014 Apr;35:51-5. (PMID: 24145152)
      J Cell Sci. 2004 Jul 1;117(Pt 15):3189-99. (PMID: 15226395)
      Oncogene. 2013 Jun 20;32(25):3080-90. (PMID: 22824798)
      PLoS One. 2014 Nov 12;9(11):e112542. (PMID: 25391145)
      Am J Physiol Cell Physiol. 2011 Apr;300(4):C723-42. (PMID: 21209361)
      Dev Cell. 2017 Oct 9;43(1):24-34.e5. (PMID: 28943240)
      Front Oncol. 2019 Sep 18;9:843. (PMID: 31620357)
      J Cell Biol. 2010 Feb 22;188(4):547-63. (PMID: 20156964)
      Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21354-21360. (PMID: 31601738)
      Curr Opin Cell Biol. 2020 Aug;65:112-121. (PMID: 32688213)
      Front Oncol. 2020 Mar 31;10:360. (PMID: 32296634)
    • Contributed Indexing:
      Keywords: breast cancer; endocytosis; heparan-sulfate proteoglycans; tumor-targeting peptide; vesicular traffic
    • Accession Number:
      0 (Cations)
      0 (Heparan Sulfate Proteoglycans)
      0 (Peptides)
    • Publication Date:
      Date Created: 20201110 Date Completed: 20210308 Latest Revision: 20210308
    • Publication Date:
      20231215
    • Accession Number:
      PMC7663799
    • Accession Number:
      10.3390/ijms21218282
    • Accession Number:
      33167372